|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic alterations in pancreatic cancer显示文摘The diagnosis of pancreatic cancer is devastating for patients and their relatives as the incidence rate is approximately the same as mortality rate. Only a small percentage, which ranges from 0.4% to 4% of patients who have been given this diagnosis, will be alive at five years. At the time of diagnosis, 80% of pancreatic cancer patients have unresectable or metastatic disease. Moreover, the therapeutic alternatives offered by chemotherapy or radiotherapy are few, if not zero. For all these reasons, there is an imperative need of analyzing and understanding the primitive lesions that lead to invasive pancreatic adenocarcinoma. Molecular pathology of these lesions is the key of our understanding of the mechanisms underlying the development of this cancer and will probably help us in earlier diagnosis and better therapeutic results. This review focuses on medical research on pancreatic cancer models and the underlying genetic alterations. | Muhammad Wasif Saif Lena Karapanagiotou Kostas Syrigos | 2007 | World Journal of Gastroenterology2007，13，33： | 10 |
| 2 | Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma显示文摘Objective:Oral squamous-cell carcinoma(OSCC)accounts for >90% of oral cancers affecting adults mostly between the fourth to seventh decades of life.The most common OSCC treatment is concomitant chemoradiotherapy(CCRT)having both locoregional and distant control,but CCRT has acute and chronic toxic effects on adjacent normal tissue.This study aimed to determine the side effects of CCRT on the oral mucosa and to characterize the clinicopathology of oral lesions in patients with OSCC.Methods:This descriptive,cross-sectional study was certified by the Ethical Review Committee(UHS/Education/126-12/2728)of the University of Health Sciences,Lahore,Pakistan.OSSC patients(n=81)with various histological subtypes,grades,and stages were recruited,and findings on their oral examination were recorded.These patients received 70,90,and 119 Gy of radiotherapy dosages in combination with the chemotherapy drugs cisplatin and 5-fluorouracil.Data were analyzed using SPSS 20.0.Results:The most common presentation of OSCC was a nonhealing ulcer(63%) involving tongue(55.6%).Clinical findings included mucositis(92.6%)and xerostomia of mild,moderate,and severe degrees in 11.1%,46.9%,and 35.8% cases,respectively.Ulcers(87.7%),palpable lymph nodes(64.2%),limited mouth opening(64.2%)and fistula(40.7%) were also observed.In females,the association of radiotherapy dosage with limited mouth opening,xerostomia,and histological grading was statistically significant(P<0.05).The association of chemotherapy drugs with xerostomia(P=0.003)was also statistically significant.Conclusions:CCRT induced mucositis,xerostomia,and trismus in patients with OSCC. | Sadia Minhas Muhammad Kashif Wasif Altaf Nadeem Afzal Abdul Hanan Nagi | 2017 | Cancer Biology & Medicine2017，14，2： | 6 |
| 3 | Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer显示文摘Ziv-afilbercept(Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor(VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG 1. Recently, a randomized, open-label, phase Ⅲ study compared 5-fluorouracil, leucovorin, irinotecan(FOLFIRI)/Ziv with FOLFIRI/placebo in patients who had been previously treated with oxaliplatin based chemotherapy for metastatic colon cancer(mC RC). Patients who had received prior bevacizumab therapy were also eligible. This study showed that the addition of Ziv improved overall survival with median survival time of 13.5 mo vs 12.06 mo in ziv vs placebo arm. Ziv also improved progression free survival from 4.67 mo to 6.9 mo with a response rate of 19.8% in the Ziv/FOLFIRI group vs 11.1% in FOLFIRI alone group. This led to the approval of Ziv in combination with FOLFIRI in metastatic colon cancer patients treated with prior oxaliplatin regimens. The mostcommon side effects were diarrhea, stomatitis, fatigue, hypertension, weight loss, loss of appetite, abdominal pain, and headache. As the use of Ziv has become more widespread in oncology practices, familiarity with the toxicity profile of the drug and the use of practice guidelines for their treatment has become increasing important. This review will address the toxicities noted in trials using Ziv for the treatment of mC RC, and will provide recommendations for toxicity management. | Muhammad Wasif Saif Valerie Relias Kostas Syrigos Krishna S Gunturu | 2014 | World Journal of Clinical Oncology2014，5，5： | 5 |
| 4 | Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction显示文摘Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial ushing, erythema, pruritis, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9th and 10th infusions, she developed fever to a maximum of 38.3℃ with stable hemodynamic status despite medications. During 11th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8℃, BP dropped to 95/43 mm Hg, pulse of 116/min and O2 saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer. | M Wasif Saif Shailja Roy Leslie Ledbetter Jennifer Madison Kostas Syrigos | 2007 | World Journal of Gastroenterology2007，13，39： | 4 |
| 5 | Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis显示文摘Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma. More than 50% of patients have some site of extra-nodal involvement at diagnosis, including the gastrointestinal tract and bone marrow. However, a diffuse large B-cell lymphoma presenting as acute pancreatitis is rare. A 57-year-old female presented with abdominal pain and matted lymph nodes in her axilla. She was admitted with a diagnosis of acute pancreatitis. Abdominal computed tomography (CT) scan showed diffusely enlarged pancreas due to infiltrative neoplasm and peripancreatic lymphadenopathy. Biopsy of the axillary mass revealed a large B-cell lymphoma. The patient was classified as stage Ⅳ, based on the Ann Arbor Classification, and as having a high-risk lymphoma, based on the International Prognostic Index. She was started on chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone). Within a week after chemotherapy, the patient’s abdominal pain resolved. Follow-up CT scan of the abdomen revealed a marked decrease in the size of the pancreas and peripancreatic lymphadenopathy. A literature search revealed only seven cases of primary involvement of the pancreas in B-cell lymphoma presenting as acute pancreatitis. However, only one case of secondary pancreatic involvement by B-cell lymphoma presenting as acute pancreatitis has been published. Our case appears to be the second report of such a manifestation. Both cases responded well to chemotherapy. | M Wasif Saif Sapna Khubchandani Marek Walczak | 2007 | World Journal of Gastroenterology2007，13，36： | 4 |
| 6 | Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States显示文摘AIM:To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer(GEC)in a real-world treatment setting. METHODS:Patients with claims between 2004 and 2005 were identified from the Thomson Reuters MarketScan databases.Capecitabine regimens were compared with 5-fluorouracil(5-FU)and other chemotherapy regimens,and were stratified by treatment setting. RESULTS:We identified 1013 patients with GEC:approximately half had treatment initiated with a 5-FU regimen,whereas 11%had therapy initiated with a capecitabine regimen.The mean capecitabine dose overall was 2382±1118 mg/d,and capecitabine was used as monotherapy more often than in combination. Overall,5-FU regimens were the most common treatment option in neoadjuvant and adjuvant settings, while other non-capecitabine regimens were used more widely in first-and second-line settings.The overall unadjusted complication rate for capecitabine regimens was about half of that seen with 5-FU regimens.In multivariate analyses,capecitabine recipients had a 51%(95%CI:26%-81%)lower risk of developing any complication than 5-FU recipients did.The risk of developing bone marrow,constitutional,gastrointestinal tract,infectious,or skin complications was lowerwith capecitabine therapy than with 5-FU.CONCLUSION:Capecitabine appeared to have a favorable side effect profile compared with 5-FU,which indicates that it may be a treatment option for GEC. | Muhammad Wasif Saif Nianwen Shi Susan Zelt | 2009 | World Journal of Gastroenterology2009，15，35： | 3 |
| 7 | Endoscopic imaging:How far are we from real-time histology?显示文摘Currently,in gastrointestinal endoscopy there is increasing interest in high resolution endoscopic technologies that can complement high-definition white light endoscopy by providing real-time subcellular imaging of the epithelial surface.These 'optical biopsy' technologies offer the potential to improve diagnostic accuracy and yield,while facilitating real-time decision-making.Although many endoscopic techniques have preliminarily shown high accuracy rates,these technologies are still evolving.This review will provide an overview of the most promising high-resolution imaging technologies,including high resolution microendoscopy,optical coherence tomography,endocytoscopy and confocal laser endoscopy.This review will also discuss the application and current limitations of these technologies for the early detection of neoplasia in Barrett's esophagus,ulcerative colitis and colorectal cancer. | Richa Shukla Wasif M Abidi Rebecca Richards-Kortum Sharmila Anandasabapathy | 2011 | World Journal of Gastrointestinal Endoscopy2011，3，10： | 3 |
| 8 | Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis显示文摘There are differences between African-American and white patients with colorectal cancer, concerning their characteristics before and after diagnosis. Whites are more likely to adhere to screening guidelines. This is also the case among people with positive family history. Colorectal cancer is more frequent in Blacks. Studies have shown that that since 1985, colon cancer rates have dipped 20% to 25% for Whites, while rates have gone up for African-American men and stayed the same for African-American women. Overall, African-Americans are 38% to 43% more likely to die from colon cancer than are Whites. Furthermore, it seems that there is an African-American predominance in right-sited tumors. African Americans tend to be diagnosed at a later stage, to suffer from better differentiated tumors, and to have worse prognosis when compared with Whites. Moreover, less black patients receive adjuvant chemotherapy for resectable colorectal cancer or radiation therapy for rectal cancer. Caucasians seem to respond better to standard chemotherapy regimens than AfricanAmericans. Concerning toxicity, it appears that patients of African-American descent are more likely to develop 5-FU toxicity than Whites, possibly because of their different dihydropyridine dehydrogenase status. Last but not least, screening surveillance seems to be higher among white than among black long-term colorectal cancer survivors. Socioeconomic and educational status account for most of these differences whereas little evidence exists for a genetic contribution in racial disparity. Understanding the nature of racial differences in colorectal cancer allows tailoring of screening and treatment interventions. | Anastasios Dimou Kostas N Syrigos Muhammad Wasif Saif | 2009 | World Journal of Gastroenterology2009，15，30： | 2 |
| 9 | IGF system in cancer: from bench to clinic显示文摘 | Jorge Chaves Muhammad Wasif Saif | 2011 | Anti-Cancer Drugs2011，，3： | 2 |
| 10 | MEMS中气体运动的若干微尺度效应显示文摘宏观流动到微流动不单是“量”的变化,而且有“质”的不同。在微流动中,由于微尺度效应,主导流动的作用力发生变化,惯性力不再占主导地位;在宏观尺度流动中可以忽略的表面效应和壁面滑移等现象,开始凸现出来,这就导致了微流动中出现了与宏观流动不同的现象和规律。本文研究微流动问题中的若干微尺度效应:包括微喷管中气体流动的特性、微槽道中的稀薄气体效应和分子泵内的流动问题。这些研究对于设计和开发新的微机械机电设备是非常重要的。 | 朱克勤 Dambricourt Pierre 郝鹏飞 Zahid Wasif Ali 尹游兵 | 2008 | 实验流体力学2008，22，B12： | 2 |
| 11 | Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?显示文摘Pancreatic adenocarcinoma(usually referred to aspancreatic cancer) is a highly lethal and aggressive malignancy with a disease-related mortality almost equaling its incidence, and one of the most challenging cancers to treat. The notorious resistance of pancreatic cancer not only to conventional cytotoxic therapies but also to almost all targeted agents developed to date, continues to puzzle the oncological community and represents one of the biggest hurdles to reducing the death toll from this ominous disease. This editorial highlights the most important recent advances in preclinical and clinical research, with regards to targeted therapeutics for pancreatic cancer, outlines current challenges and provides an overview of potential future perspectives in this rapidly evolving field. | Dimitra Grapsa Muhammad Wasif Saif Konstantinos Syrigos | 2015 | World Journal of Gastrointestinal Oncology2015，7，10： | 2 |
| 12 | Capecitabine: an overview of the side effects and their management显示文摘 | Muhammad Wasif Saif Nikos A. Katirtzoglou Kostas N. Syrigos | 2008 | Anti-Cancer Drugs2008，，5： | 1 |
| 13 | Dihydropyrimidine dehydrogenase deficiency in an Indian population显示文摘 | Muhammad Wasif Saif Lori Mattison Tom Carollo Hany Ezzeldin Robert B. Diasio | 2006 | Cancer Chemotherapy and Pharmacology2006，，3： | 1 |
| 14 | Diabetes and bums :retrospective cohort study 显示文摘 | McCampbell B Wasif N Rabbitts A | 2002 | J Burn Care Rehabil2002，23，3： | 1 |
| 15 | MR versus uhra- sonography and mammography for preoperative assess- ment of breast cancer 显示文摘 | Wasif N Garreau J Terando A | 2009 | Am Surg2009，75，10： | 1 |
| 16 | Have the Ameri- can College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sen- tinel lymph node dissection显示文摘 | Robinson KA Pockaj BA Wasif N | 2014 | Am J Surg2014，208，6： | 1 |
| 17 | Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions显示文摘 | Muhammad Wasif Saif Kristin Kaley Edward Chu M. Sitki Copur | 2010 | Clinical Colorectal Cancer2010，，5： | 1 |
| 18 | Predictors of occult nodal metastasis in colon cancer: Results from a prospective multicenter trial显示文摘 | Nabil Wasif Mark B. Faries Sukamal Saha Roderick R. Turner David Wiese Martin D. McCarter Perry Shen Alexander Stojadinovic Anton J. Bilchik | 2010 | Surgery2010，，3： | 1 |
| 19 | Survey of ASCO members on management of sentinel node micrometastasis in breast caneer;variation in treatment recommendations according to specialty显示文摘 | Wasif N Ye X Giuliano AE | 2009 | Ann Surg Oncol2009，16，9： | 1 |
| 20 | Two-stage cultivation of two Chlorella sp. strains by simultaneous treatment of brewery wastewater and maximizing lipid productivity显示文摘 | Wasif Farooq Young-Chul Lee Byung-Gon Ryu Byung-Hyuk Kim Hee-Sik Kim Yoon-E. Choi Ji-Won Yang | 2013 | Bioresource Technology2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员